Patients are suffering now since Health Insurance Review & Assessment Service and Pfizer are at tug-of-war over the insurance benefit
Non-small cell lung cancer(NSCLC) drug, Xalkori, is now on the issue of being insurance benefit. NSCLC patients are suffering from a tug-of-war between HIRA and Pfizer.
Not only Pfizer, HIRA also recognizes the need for benefits. However, last November, HIRA made a decision on Xalkori as non-ins...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
